Novartis Japan Looks To Capitalize On Drug Approval Spurt, Submits NDA For Everolimus
This article was originally published in The Pink Sheet Daily
Product launches will follow listing by Japan’s Central Social Insurance Medical Council.
You may also be interested in...
TOKYO - Novartis CEO Daniel Vasella told an audience in Tokyo last week that "the current [global financial] situation creates opportunities because [Novartis has] a very solid free cash flow and most [Novartis] companies have a solid free cash flow and are not in a highly indebted environment.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.